Tagrisso with the addition of chemotherapy approved in Japan as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer

Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care

Truqap plus Faslodex approved in Japan for patients with advanced HR-positive breast cancer

First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations

Asahi Kasei Medical and AW Technologies enter exclusive distribution agreement for TrachFlush in Japan

Glenmark Life Sciences inks CDMO supply deal with a Japanese pharma innovator

Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator

Parexel collaborates with Japanese Foundation for cancer research

Collaboration streamlines patient access to oncology clinical trials

AOB Pharma and Maruho enter into an agreement for AOB’s B244 for treatment of atopic dermatitis in Japan

The deal includes upfront payments, milestone payments and ongoing royalties

Biocon Biologics signs distribution partnership with Sandoz for Adalimumab BS Subcutaneous Injection in Japan

The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio

Astellas, BioLabs and Mitsui Fudosan collaborate to enhance life science ecosystems in Tsukuba and Kashiwa-no-ha, Japan

Astellas stands on the forefront of healthcare change to turn innovative science into value for patients

Shilpa Pharma Lifesciences’ Unit II, Raichur, Karnataka clears PMDA Japan, GMP inspection

The inspection has concluded successfully on 1st September 2023 without any critical/major observation

Lynparza plus abi/pred approved in Japan for treatment of prostate cancer

First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent